sb 203580 has been researched along with clonidine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (clonidine) | Trials (clonidine) | Recent Studies (post-2010) (clonidine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 13,692 | 2,044 | 1,394 |
| Protein | Taxonomy | sb 203580 (IC50) | clonidine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.101 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0115 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 5.365 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.21 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 5.365 | |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.002 | |
| Nischarin | Rattus norvegicus (Norway rat) | 0.3662 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beitz, AJ; Kim, SJ; Lee, JH; Oh, SB; Roh, DH; Yeo, JH; Yoon, SY | 1 |
1 other study(ies) available for sb 203580 and clonidine
| Article | Year |
|---|---|
Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents; Blood Pressure; Clonidine; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Hyperalgesia; Imidazoles; Male; Mice; Motor Activity; Organoplatinum Compounds; Oxaliplatin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Spinal Cord; Spinal Cord Dorsal Horn | 2016 |